OnePin Peptide Library · Repair & Recovery
KPV
Lysine-Proline-Valine · KPV Tripeptide · Lys-Pro-Val
KPV is a synthetic tripeptide (Lys-Pro-Val) derived from the C-terminal end of alpha-melanocyte stimulating hormone (alpha-MSH). It retains the potent anti-inflammatory signaling of the parent hormone while lacking the melanogenic (skin darkening) and appetite-suppressive properties associated with the full alpha-MSH sequence. KPV exerts its anti-inflammatory effects primarily through suppression of the NF-kB signaling pathway, one of the master regulators of inflammatory gene expression. It has been studied in the context of inflammatory bowel disease, mucosal inflammation, skin inflammation, and systemic inflammatory conditions. Its small size (3 amino acids) makes it highly stable, easily absorbed, and amenable to syringe mixing with most other peptides.
SubQ: Any time of day. Oral: Take on empty stomach for GI targeting (PepT1 transporter absorption). Wait 30 minutes before eating.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
KPV suppresses the NF-kB inflammatory signaling cascade by preventing nuclear translocation of NF-kB p65 subunit, thereby reducing transcription of pro-inflammatory cytokines including IL-1beta, IL-6, IL-8, and TNF-alpha. Unlike NSAIDs which target COX enzymes or corticosteroids which broadly suppress immune function, KPV's NF-kB modulation is a more upstream and targeted anti-inflammatory mechanism. KPV also interacts with melanocortin receptors (MC1R, MC3R, MC5R) but with reduced affinity compared to full-length alpha-MSH, which explains its minimal melanogenic activity. The peptide has been shown to penetrate inflamed mucosal tissue and accumulate at sites of intestinal inflammation, making it particularly relevant for GI applications.
KPV suppresses the NF-kB inflammatory signaling cascade by preventing nuclear translocation of NF-kB p65 subunit, thereby reducing transcription of pro-inflammatory cytokines including IL-1beta, IL-6, IL-8, and TNF-alpha. Unlike NSAIDs which target COX enzymes or corticosteroids which broadly suppress immune function, KPV's NF-kB modulation is a more upstream and targeted anti-inflammatory mechanism. KPV also interacts with melanocortin receptors (MC1R, MC3R, MC5R) but with reduced affinity compared to full-length alpha-MSH, which explains its minimal melanogenic activity. The peptide has been shown to penetrate inflamed mucosal tissue and accumulate at sites of intestinal inflammation, making it particularly relevant for GI applications.
What to expect
Days 1-7: Some users report early improvements in GI comfort and reduced bloating. Anti-inflammatory signaling begins immediately but clinical effects take time.
Weeks 2-4: Consistent improvement in gut comfort and bowel function. Skin inflammation improvements noticeable if applicable. Systemic inflammation markers may begin to improve.
Weeks 4-12: Cumulative anti-inflammatory and mucosal healing effects. Best results when combined with BPC-157 for gut healing. Inflammatory markers (CRP, ESR) may show measurable improvement.
Evidence
The honest take
IBD / Colitis treatment
Animal colitis models show significant efficacy. Mechanism (NF-kB suppression in gut mucosa) is well-characterized. Not a validated IBD treatment in humans. Promising preclinical data.
In vitro and limited in vivo data support anti-inflammatory effects on keratinocytes and dermal tissue. Topical formulations studied. Not a validated dermatological treatment.
Confirmed. KPV retains the anti-inflammatory fragment of alpha-MSH without the melanocortin receptor activation responsible for skin darkening. This is its key advantage over MT-II for anti-inflammatory purposes.
Interactions & stacking
What's safe to combine, and what belongs in a separate pin.
Safe & synergistic
Keep separate
Side effects & safety
Commonly reported
- Generally very well tolerated (simple tripeptide)
- Minimal injection site reactions
- Rare reports of mild fatigue
Less common & notes
- KPV is a naturally occurring fragment of alpha-MSH with an excellent safety profile.
- Unlike full-length alpha-MSH or MT-II, KPV does not cause significant melanogenesis (skin darkening) or appetite changes.
- Individuals with autoimmune conditions should consult their physician as NF-kB modulation could theoretically affect immune regulation.
- Long-term human safety data is not established.
Pharmacokinetics
Storage. Store unreconstituted vials frozen (-20C) or refrigerated (2-8C). After reconstitution with BAC water, refrigerate at 2-8C. Stable for 28-30 days. Small tripeptide structure confers favorable stability. Protect from light.
Regulatory status
KPV is not FDA-approved for any indication. Available as a research peptide and through compounding pharmacies. WADA status is not specifically addressed. Not a scheduled or controlled substance.
Put it to work
Calculate, log & track
Open KPV straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open KPV in the app →Go deeper
The guide & community
The complete KPV walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗